What You'll Learn
Table of Contents
How Much Comes Back
This is one of the better-quantified questions in the field, because enough discontinuation data now exists to pool.
Pooling randomised trials, non-randomised studies and observational data on discontinuation, mean regain was 2.20 kg for liraglutide and 9.69 kg for semaglutide or tirzepatide — larger in absolute terms for the drugs that produced the larger initial loss.
PubMed PMID: 41938838 ↗Bottom line: Roughly half to two-thirds of the lost weight typically returns within a year of stopping. That is the central finding, and it is consistent across the studies pooled.
Legion Whey+
The muscle you keep is what keeps your resting metabolic rate up, and protein plus lifting is how you keep it. That is a food problem first; a whey isolate is the cheapest way to close the gap on the days food does not get you there.
Check price at Legion →Disclosure: we earn a commission if you buy through this link, at no extra cost to you. It does not change what this page says. Supplements do not treat or replace a GLP-1 medication, and nothing here is medical advice.
Why The Numbers Differ By Drug
The pooled analysis found a mean regain of about 2.20 kg for liraglutide against 9.69 kg for semaglutide or tirzepatide. That gap is not evidence that one drug is more ‘sticky’ than another — it largely tracks how much weight each produced in the first place.
Semaglutide and tirzepatide drive substantially larger losses (see the trial figures), so there is simply more to regain. Proportionally the picture is far closer than the absolute numbers suggest.
What Else Reverses
Weight is the visible part. The cardiometabolic improvements that accumulate during treatment — the blood pressure, lipid and glycaemic changes — also drift back.
Following the original STEP-1 population after semaglutide was stopped, participants regained weight and the cardiometabolic improvements accrued during treatment reversed toward baseline.
Full study on PMC ↗Recurrence, Not Failure
Current clinical guidelines treat obesity as a chronic, relapsing condition. Under that framing, regain after stopping treatment is disease recurrence — the same category of event as blood pressure rising after stopping an antihypertensive, or reflux returning after stopping a proton-pump inhibitor.
This is not a rhetorical softening. It has a practical consequence: if the underlying condition is chronic, then ‘how long do I take this for?’ is a different question from ‘when do I finish the course?’, and it belongs with a prescribing clinician rather than a fixed rule.
Bottom line: The homeostatic systems that defend body weight do not switch off during treatment — they are being opposed. Remove the opposition and they resume.
What To Decide Before You Stop
- Whether stopping is the goal at all. For a chronic condition, indefinite treatment may be the clinical plan rather than a failure of one.
- What replaces the appetite suppression. Structure that was carried by the medication has to be carried by something else.
- Whether muscle was protected on the way down. Lean mass lost during the loss phase makes the maintenance phase harder — see the muscle-loss guide.
- Dose tapering versus stopping outright. Entirely a clinical decision, and a conversation worth having before rather than after.
Important: Never stop, taper or restart a prescription medication based on an article. These are the questions to bring to your prescribing clinician, not answers to act on alone.
